Organon & Co. Common Stock vs Public Service Enterprise Group Incorporated Common Stock — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while Public Service Enterprise Group Incorporated Common Stock trades at $69.9 (market cap $35.12B). The key difference: Public Service Enterprise Group Incorporated Common Stock is far larger — about 9.7× Organon & Co. Common Stock's market cap, and Public Service Enterprise Group Incorporated Common Stock pays the higher dividend (3.8%). Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Public Service Enterprise Group Incorporated Common Stock for 0 Days on average.
| OGN | PEG | |
|---|---|---|
Market Cap | $3.62B | $35.12B |
Volume | 2,892,999 | 4,400,164 |
Sector | Health | Utilities |
52-Week High | $13.81 | $86.95 |
52-Week Low | $5.70 | $66.56 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $11.04B | $59.61B |
Dividend Yield | 0.58% | 3.8% |
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Public Service Enterprise Group (PEG) trades at $70.47, down 0.41% on the day, showing neutral technical signals with support at $70 and resistance at $71. The company maintains solid fundamentals with a 17.53 P/E ratio and consistent earnings beats in recent quarters, though Q3 2026 results are pending. Revenue grew to $12.17B in 2025 with a healthy 16.04% net income margin, while analyst consensus remains mixed with a $83.40 price target suggesting potential upside.
PEG presents a stable utility investment with regulated growth and nuclear assets supporting a 6-8% earnings outlook. Key risks include regulatory approvals for capex plans and interest rate sensitivity. Institutional buying and a 15-year dividend growth streak add appeal, but recent CEO stock sales and proximity to 52-week lows warrant caution amid sector volatility.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →Public Service Enterprise Group Incorporated is a New Jersey-based utility holding company operating through Public Service Electric and Gas Co. (PSE&G), which transmits and distributes electricity and distributes natural gas, and PSEG Power, which operates the Salem and Hope Creek nuclear generating stations. It also runs the Long Island Power Authority's electric system under contract via PSEG Long Island.
Read more on PEG →